BPC-157 is often discussed as though its stability is a straightforward question. But once a peptide is reconstituted into a liquid solution, the stability picture becomes considerably more complicated. Two recent stability studies shared by PeptideCrafters provide an interesting look at what can happen to reconstituted BPC-157 over a three-month period. The results suggest that both time and temperature may have a meaningful effect on measured BPC-157 purity and content. Importantly, these results should be viewed as laboratory stability observations rather than a universal expiration date or storage recommendation for every BPC-157 preparation. How the studies were conducted The studies examined reconstituted BPC-157 at different time points using analytical testing. The measurements included HPLC purity and measured BPC-157 content, with testing performed through Janoshik Analytical according to the study description. The first study examined refrigerated samples over three months. The second study went a step further by comparing samples maintained under refrigerated conditions with samples kept at room temperature. That comparison is particularly interesting because temperature is an important variable in peptide stability. FDA documentation on BPC-157 notes that peptide stability can be affected by environmental and formulation factors including temperature, pH, concentration, impurities and other conditions. Study 1: Refrigerated BPC-157 over three months The first study began with a measured BPC-157 content of approximately 11.1 mg and an HPLC purity of 99.885%. After the first month under refrigerated conditions, there was relatively little change, with approximately 99.5% content retention reported. By month two, however, the numbers changed substantially. Measured content fell to approximately 9.767 mg, while HPLC purity fell to approximately 95.119%. That represented a much larger change than was observed during the first month. Then something interesting happened.

NAD+ has gone from an obscure biochemical molecule to one of the most discussed targets in longevity and healthy-aging research. And there is a reason for that. Nicotinamide adenine dinucleotide, or NAD+, is essential for cellular energy metabolism and participates in processes including mitochondrial function, DNA repair and cellular signaling. But there is an important distinction between understanding what NAD+ does biologically and proving that increasing NAD+ in humans produces meaningful health benefits. In 2026, the human evidence is becoming much more interesting. It is also becoming clear that the story is more complicated than simply saying: "NAD+ declines with age, so everyone should take an NAD+ booster." What exactly is NAD+? NAD+ is a molecule found throughout the body's cells. It acts as an essential cofactor in numerous biochemical reactions, including those involved in energy production and cellular metabolism. It is also involved in reactions associated with DNA repair and cellular signaling. Because NAD+ is so deeply integrated into cellular biology, researchers have become interested in whether declining NAD+ availability contributes to aspects of aging and age-associated disease. The basic biology is well established. The bigger question is what happens when researchers deliberately increase NAD+ availability in humans. That is where clinical research becomes particularly important. Does NAD+ really decline with age? This is one of the claims that needs some nuance. A number of studies have reported age-related reductions in NAD+ or NAD-related metabolites in particular tissues and populations. However, the evidence is not uniform across all human tissues, and the magnitude of age-related decline is not established as a simple "half by age 50" rule. A 2025 review of NAD+ precursor research in human aging noted that an age-related decline in NAD+ has been consistently observed only in a limited number of human studies. The authors also emphasized that clinical trials of NAD+ precursors have so far shown more limited effects than many preclinical studies might suggest.